Lupin Successfully Resolves False Labeling Action Related to Ramipril

Taylor v. Lupin Pharmaceuticals
  • Eastern District, TN

Successfully defended Lupin Pharmaceuticals against claims of false and defective labeling and advertising Ramipril, an ACE inhibitor for high blood pressure.

The case centered on the federal preemption defense and the Hatch-Waxman Act applicable to generic pharmaceuticals.*